tamoxifeno farmoz
edupharma, uab - tamoksifenas - tabletės - 20 mg - tamoxifen
tamoxifeno farmoz
nenurodyta - tamoksifenas - tabletės - 20 mg - tamoxifen
tamoxifen ebewe
sandoz d.d. - tamoksifenas - tabletės - 20 mg; 10 mg - tamoxifen
tamoxifen-teva
teva pharma b.v. - tamoksifenas - plėvele dengtos tabletės - 20 mg - tamoxifen
tamoxifen mylan
lex ano, uab - tamoksifenas - tabletės - 20 mg - tamoxifen
tamoxifen 20 heumann
nenurodyta - tamoksifenas - tabletės - 20 mg - tamoxifen
tamoxifen
tillomed laboratories ltd. - tamoksifenas - tabletės - 20 mg - tamoxifen
meditam
nenurodyta - tamoksifenas - tabletės - 20 mg - tamoxifen
temodex
nenurodyta - tamoksifenas - tabletės - 20 mg - tamoxifen
verzenios
eli lilly nederland b.v. - abemaciclib - krūties navikai - antinavikiniai vaistai - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.